TILDRAKIZUMAB for Genital psoriasis | Plaque psoriasis

Inclusion criteria

• {"criterion_text":"- Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and provide written informed consent in accordance with institutional and regulatory guidelines\n- Age ≥18 years of age at the time of signing consent\n- Diagnosis of moderate to severe psoriasis of the genital area at Screening and baseline defined as modified sPGA-G score of ≥3.\n- Presence of non-genital plaque psoriasis (BSA ≥1 %) at both Screening and Baseline.\n- Presence of psoriasis of the genital area that is inadequately controlled with topical therapy or the subject is intolerant to topical therapy\n- Negative evaluation for TB within 4 weeks before initiating IMP, defined as a negative QuantiFERON test. Subjects with a positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests are allowed if they have all of the following: •\tno history of active tuberculosis (TB) or symptoms of TB, •\ta posteroanterior chest radiograph (with associated report available at the site) performed within 3 months of Screening with no evidence of active TB (or of any other pulmonary infectious diseases), •\tif prior latent TB infection, must have history of adequate prophylaxis (per local standard of care), •\tif presence of latent TB is established, then treatment according to local country guidelines must have been followed for 4 weeks, prior to dosing in the study at Visit 2 (Week 0). A maximum of 2 QuantiFERON tests of no more than 3 weeks apart are allowed. A re-test is only permitted if the first is indeterminate; the result of the second test will then be used\n- Physical examination within normal limits or clinically acceptable limits as per the investigator prior to the first dose of study medication. The investigator is encouraged to consult with the medical monitor (or appropriate designee) if there are questions regarding the significance of any out of range values.\n- For women of childbearing potential, a negative serum pregnancy test at Screening and a negative urine pregnancy test within 24 hours prior to the first dose of study medication\n- Subject must be in good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination, clinical laboratories, and urinalysis."}

Exclusion criteria

• {"criterion_text":"- Predominantly non-plaque forms of psoriasis specifically erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new-onset guttate psoriasis.\n- Any concurrent medical condition or uncontrolled, clinically significant systemic disease (e.g., renal failure, heart failure, hypertension, liver disease, diabetes, or anemia) that, in the opinion of the Investigator, could jeopardize subject safety or compliance with the protocol.\n- Myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to the first IMP dose.\n- Women of childbearing potential who are pregnant, intend to become pregnant during the trial or within 17 weeks of completing the trial, or are lactating.\n- Positive human immunodeficiency virus (HIV) test result, hepatitis B virus (HBV), or hepatitis C virus (HCV) testing The following algorithm shall be followed for all subjects to evaluate this exclusion criteria: a. Subjects with positive anti-HIV antibody shall be excluded from the study b. Subjects with a Hepatitis B surface antigen (HBsAg) positive test will be excluded from the study. c. Subjects with a HBsAg negative test shall be tested for Hepatitis B core antibody (Anti-HBc). Subjects with negative Anti-HBc can be included in the study. Subjects with positive Anti-HBc shall further be tested for HBV - deoxyribonucleic acid (HBV-DNA). Subjects testing negative for HBV-DNA shall be included in the study. Subjects testing positive for HBV-DNA shall be excluded from the study. In the event the HBV-DNA test cannot be performed, the subject shall NOT be considered eligible for this study. d. Subjects with HCV antibody non-reactive will be included in the study. Subjects with HCV antibody reactive, shall be tested for HCV - ribonucleic acid (HCV RNA). If tested negative, subject can be included in the study. Subjects with HCV-RNA positive shall be excluded from the study. In the event the HCV-RNA test cannot be performed, the subject shall NOT be considered eligible for this study.\n- Any active malignancy (including but not limited to cutaneous basal cell carcinoma, squamous cell carcinoma or melanoma).\n- Any prior malignancy within 5 years from Screening (excluding successfully treated and cured cutaneous basal cell carcinoma or squamous cell carcinoma, or in situ breast ductal carcinoma).\n- Laboratory abnormalities at Screening, including any of the following: •\tAspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal (ULN), •\tCreatinine ≥ 2 times the ULN •\tSerum direct bilirubin ≥ 1.5 mg/dl •\tWhite blood cell (WBC) count < 3.0 x 103/μL •\tPlatelet count ≤ 100,000/µl •\tHemoglobin (Hb) < 10.0 g/dl •\tAny other laboratory abnormality, that is considered clinically significant by the Investigator and which, in the opinion of the Investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results\n- Significant risk of suicidality at the Screening assessment based on the Investigator’s judgment or, if appropriate, as indicated by: a response of “yes” within the last 6 months to question 4 or 5 in the suicidal ideation section, or any response in the behavioral section of C-SSRS\n- Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, for example, a combination of the following: (1) oral contraceptive, depo progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy). Contraceptive methods must be practiced upon entering the study and through 17 weeks after the last dose of IMP. If a subject discontinues prematurely, the contraceptive method must be practiced for 17 weeks following final administration of IMP. A follicle-stimulating hormone (FSH) test should be performed to confirm menopause for those women with no menses for less than 1 year.\n- Previous enrollment (randomized and received IMP) in this study.\n- Live viral or bacterial vaccination within 4 weeks prior to baseline, or planned live viral or bacterial vaccination during the trial\n- Subject has evidence of skin conditions that would interfere with clinical assessments.\n- Subject has prolonged sun exposure or use of tanning booths or other ultraviolet light sources\n- Presence of excessive hair, tattoos, pigmentation, extensive scarring, pigmented lesions, or sunburn in the treatment area, which could make the affected plaque psoriasis BSA difficult to visualize\n- Subjects who are related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest could arise\n- Any significant organ dysfunction within 6 months prior to Screening that in the judgement of the Investigator places the subject at unacceptable risk for participation in a trial of an immunomodulatory agent\n- History of alcohol or drug abuse in the previous year in the opinion of the Investigator.\n- Known sensitivity to any of the products or any excipients to be administered during dosing (e.g. histidine, polysorbate 80, and sucrose).\n- Prior use of following therapies for treatment of psoriasis/psoriatic arthritis: a) Prior use of any investigational or approved drugs within 30 days or 5 half-lives, whichever is longer, prior to randomization. Prior use of Apremilast or other approved or investigational Janus kinase (JAK) inhibitors for the treatment of psoriatic arthritis and/or psoriasis which are not identified as permitted therapies within 5 half-lives or 15 days (whichever is longer) prior to IMP initiation. b) Use of etanercept within 4 weeks, infliximab within 8 weeks, and all other anti-TNF therapy within 3 months prior to IMP initiation c) Topical therapy within 2 weeks of randomization [including but not limited to topical Phosphodiesterase-4 enzyme (PDE-4) inhibitors (e.g. roflumilast, crisaborole) topical corticosteroids, topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol for body lesions; coal tar, salicylic acid preparations, or medicated shampoos for scalp lesions]. d) Conventional systemic therapy for psoriasis within 4 weeks prior to randomization (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, or fumaric acid esters). e) Leflunomide within 6 months prior to randomization. f) Phototherapy treatment of body within 4 weeks prior to randomization (i.e., ultraviolet B, psoralen and ultraviolet A radiation). g) Any prior use of biologics, approved or investigational, such as secukinumab, ustekinumab, ixekizumab, brodalumab, or any drugs targeting interleukin (IL)-17, IL-23, or the IL-12/IL- 23-shared p40 molecule or any biosimilars for each for the treatment of psoriasis, psoriatic arthritis, or any other indication that could impact the assessment of psoriasis h) Prior use of B-cell depleting agent or T-cell inhibitor within 12 months of Screening\n- Currently enrolled in any investigational study\n- Planned surgical intervention between baseline and the Week 16 evaluation for a pre-treatment condition.\n- Active infection or history of infections as follows: a. any active infection (bacterial, fungal or viral) for which systemic anti-infectives were used within 28 days prior to first IMP dose, with the last dose having been received within 7 days of Screening, b. a serious infection, defined as requiring hospitalization or intravenous (IV) anti-infectives within 8 weeks prior to the first IMP dose, with the last dose having been received within 7 days of Screening, c. recurrent or chronic infections, e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis, or other active infection that, in the opinion of the Investigator, might cause participation in this study to be detrimental to the subject"}

Primary endpoints

• {"endpoint_text":"- Tildrakizimab vs placebo at week 16: Proportion of subjects with a modified sPGA-G score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline","definition_or_measurement_approach":"Measured at Week 16 using the modified static Physician’s Global Assessment of Genitalia (sPGA-G); endpoint is the proportion of subjects achieving sPGA-G of 0 or 1 with ≥2-point reduction from baseline."}

Secondary endpoints

• {"endpoint_text":"- Proportion of subjects, with a baseline score of ≥4, who achieve at-least 4-point improvement in weekly average of GPI- NRS","definition_or_measurement_approach":"Weekly average of the Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS); proportion achieving ≥4-point improvement from baseline in subjects with baseline ≥4."}
• {"endpoint_text":"- Mean change from baseline in the affected BSA","definition_or_measurement_approach":"Mean change from baseline in affected body surface area (BSA) assessed per site procedures."}
• {"endpoint_text":"- Change from baseline in GPSS total score and individual items scores","definition_or_measurement_approach":"Change from baseline in Genital Psoriasis Symptoms Scale (GPSS) total and individual item scores."}
• {"endpoint_text":"- Proportion of subjects with PASI 75 response (≥ 75% reduction from baseline in PASI score)","definition_or_measurement_approach":"Proportion achieving ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI)."}
• {"endpoint_text":"- Proportion of subjects with PASI 90 response (≥ 90% reduction from baseline in PASI score)","definition_or_measurement_approach":"Proportion achieving ≥90% reduction from baseline in PASI."}
• {"endpoint_text":"- Proportion of subjects with PASI 100 response (100% reduction from baseline in PASI score), insubjects with BSA <10%","definition_or_measurement_approach":"Proportion achieving 100% reduction from baseline in PASI (complete clearance), analyzed in subjects with baseline BSA <10%."}

Methods

• Dr-to-patient letter (K2_Recruitment material_dr_to_pt_letter) - channel: clinician-mediated letter to patients; country-specific versions present (e.g., PL, BG, HU files exist).
• Patient brochure (K2_Recruitment material_brochure / K2_Recruitment Material_Patient Brochure) - channel: printed brochure for patients; country-specific versions available (PL, BG, HU).
• Poster with flyer (K2_Recruitment material_poster_with_flyer / K2_Recruitment Material_Poster with flyer_PL) - channel: patient-facing posters/flyers for clinic/community display; country-specific versions.
• Website prototype (K2_ Recruitment material Website Prototype / Website Prototype files) - channel: study website prototype for public/participant information; country-specific variants noted.
• Patient flow chart (K2_Recruitment material_Patient Flow Chart) - channel: information given to patients explaining study visits and pathways.
• Study Visit Guide / Study Visit materials (K2_Recruitment Material_Study Visit Guide) - channel: materials provided to potential participants outlining visits and procedures.
• Patient-facing digital materials and app-related materials (PatientGO App, App Prototype, PatientGO EULA, PatientGO Privacy Policy) - channel: digital app and online resources supporting recruitment and participant engagement; country/language variants present.

Hungary

Earliest CTIS Part Ii Submission Date

18-03-2025

Latest Decision Or Authorization Date

05-09-2025

Processing Time Days

171

Number Of Sites

2

Number Of Participants

15

Poland

Earliest CTIS Part Ii Submission Date

14-04-2025

Latest Decision Or Authorization Date

27-09-2025

Processing Time Days

166

Number Of Sites

12

Number Of Participants

60

Bulgaria

Earliest CTIS Part Ii Submission Date

29-04-2025

Latest Decision Or Authorization Date

02-10-2025

Processing Time Days

156

Number Of Sites

5

Number Of Participants

30

Primary sponsor

Full Name

Sun Pharmaceutical Industries Limited

Organisation Type

Pharmaceutical company

Country Of Registered Address

India

Contract research organisations

Name

Syneos Health Inc.

Responsibilities

Recruitment and multiple sponsor duties (codes: 1,12,14,15 (recruitment),5,8,9 as listed in record)

Name

Almac Clinical Services Limited

Responsibilities

IP management: IP assembly, labeling, secondary packaging, storage, QP certification and distribution to clinical sites

Name

Clario Medical Imaging Inc.

Responsibilities

ECG Central Reading

Name

Labcorp Central Laboratory Services LP

Responsibilities

Central laboratory services (listed duty code 4)

Third parties

• {"country":"United States","full_name":"Syneos Health Inc.","duties_or_roles":"Sponsor duties codes listed: 1,12,14,15 (recruitment),5,8,9","organisation_type":"Pharmaceutical company"}
• {"country":"United Kingdom","full_name":"Umotif Limited","duties_or_roles":"Sponsor duties code 7 (as listed)","organisation_type":"Non-Pharmaceutical company"}
• {"country":"United Kingdom (Northern Ireland)","full_name":"Almac Clinical Services Limited","duties_or_roles":"IP management includes IP assembly, labeling, secondary packaging, storage, QP certification and distribution to clinical sites","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Clario Medical Imaging Inc.","duties_or_roles":"ECG Central Reading","organisation_type":"Pharmaceutical company"}
• {"country":"United Kingdom","full_name":"Neonstone Limited","duties_or_roles":"ePortal","organisation_type":"Non-Pharmaceutical company"}
• {"country":"United States","full_name":"Labcorp Central Laboratory Services LP","duties_or_roles":"Central laboratory services (sponsor duty code 4 listed)","organisation_type":"Pharmaceutical company"}